Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others.

Literature DB >> 21460130

Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others.

Joseph P Kitzmiller¹, David K Groen, Mitch A Phelps, Wolfgang Sadee.

Abstract

Genetics may account for much of the variability in our patients' responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. It also discusses the future role of pharmacogenomic testing in medicine.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2011 PMID： 21460130 PMCID： PMC3351041 DOI： 10.3949/ccjm.78a.10145

Source DB: PubMed Journal: Cleve Clin J Med ISSN： 0891-1150 Impact factor: 2.321

75 in total

Review 1. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors: Norbert Thuerauf; Jens Lunkenheimer
Journal: Eur Arch Psychiatry Clin Neurosci Date: 2006-08 Impact factor: 5.270

Review 2. CYP2D6 genotyping and the pharmacogenetics of tamoxifen.

Authors: David Flockhart
Journal: Clin Adv Hematol Oncol Date: 2008-07

3. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?

Authors: Deepak L Bhatt
Journal: JAMA Date: 2009-08-26 Impact factor: 56.272

4. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

Authors: Thomas Rau; Gerlinde Wohlleben; Henrike Wuttke; Norbert Thuerauf; Jens Lunkenheimer; Mario Lanczik; Thomas Eschenhagen
Journal: Clin Pharmacol Ther Date: 2004-05 Impact factor: 6.875

5. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.

Authors: Werner Steimer; Konstanze Zöpf; Silvia von Amelunxen; Herbert Pfeiffer; Julia Bachofer; Johannes Popp; Barbara Messner; Werner Kissling; Stefan Leucht
Journal: Clin Chem Date: 2004-06-17 Impact factor: 8.327

Review 6. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

Authors: M P Goetz; A Kamal; M M Ames
Journal: Clin Pharmacol Ther Date: 2007-09-19 Impact factor: 6.875

7. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors: Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal: Lancet Date: 2008-12-26 Impact factor: 79.321

Review 8. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Authors: Vincent O Dezentjé; Henk-Jan Guchelaar; Johan W R Nortier; Cornelis J H van de Velde; Hans Gelderblom
Journal: Clin Cancer Res Date: 2009-01-01 Impact factor: 12.531

9. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.

Authors: Marianne Gex-Fabry; Chin B Eap; Beatrice Oneda; Nicola Gervasoni; Jean-Michel Aubry; Guido Bondolfi; Gilles Bertschy
Journal: Ther Drug Monit Date: 2008-08 Impact factor: 3.681

10. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.

Authors: David A Flockhart; Dennis O'Kane; Marc S Williams; Michael S Watson; David A Flockhart; Brian Gage; Roy Gandolfi; Richard King; Elaine Lyon; Robert Nussbaum; Dennis O'Kane; Kevin Schulman; David Veenstra; Marc S Williams; Michael S Watson
Journal: Genet Med Date: 2008-02 Impact factor: 8.822

28 in total

1. Stroke Genetics Update: 2011.

Authors: John W Cole; James F Meschia
Journal: Curr Cardiovasc Risk Rep Date: 2011-12-01

2. Program in pharmacogenomics at the Ohio State University Medical Center.

Authors: Joseph P Kitzmiller; Peter J Embi; Kandamurugu Manickam; Kevin M Sweet; Mitch A Phelps; Rebecca D Jackson; Clay B Marsh; Wolfgang Sadee
Journal: Pharmacogenomics Date: 2012-05 Impact factor: 2.533

3. Documenting Pharmacogenomic Testing with CPT Codes.

Authors: Erik Hefti; Javier G Blanco
Journal: J AHIMA Date: 2016-01

Review 4. Single or dual antiplatelet therapy after PCI.

Authors: Yosuke Miyazaki; Pannipa Suwannasom; Yohei Sotomi; Mohammad Abdelghani; Karthik Tummala; Yuki Katagiri; Taku Asano; Erhan Tenekecioglu; Yaping Zeng; Rafael Cavalcante; Carlos Collet; Yoshinobu Onuma; Patrick W Serruys
Journal: Nat Rev Cardiol Date: 2017-02-09 Impact factor: 32.419

5. The incorporation of predictive genomic testing into genetic counseling programs.

Authors: Ryan Noss; Rachel Mills; Nancy Callanan
Journal: J Genet Couns Date: 2014-03-02 Impact factor: 2.537

6. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.

Authors: Paulo Caleb Junior Lima Santos; Carla Luana Dinardo; Isolmar Tadeu Schettert; Renata Alonso Gadi Soares; Liz Kawabata-Yoshihara; Isabela Martins Bensenor; José Eduardo Krieger; Paulo Andrade Lotufo; Alexandre Costa Pereira
Journal: Eur J Clin Pharmacol Date: 2012-09-19 Impact factor: 2.953